本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600645 证券简称：中源协和 中源协和细胞基因工程股份有限公司 2025 年第三季度报告 中源协和细胞基因工程股份有限公司 2025 年第三季度报告 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 376,090,468.00 | - ...

证券代码：600645 证券简称：中源协和 公告编号：2025-041 重要内容提示： ●拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙）（以下 简称"天健所"） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1. 基本信息 中源协和细胞基因工程股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 年 7 月 日 | 18 | 组织形式 | | 特殊普通合伙 | | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 | | 128 | 号 | | | | 首席合伙人 | 钟建国 上年末合伙人数量 | | | | 241 | 人 | | 上年末执业人 | 注册会计师 | | | | 2,356 | 人 | | 员数量 | 签署过证券服务业务审计报告的注册会计师 | | | | 904 | ...

Core Viewpoint - The company is utilizing temporarily idle raised funds for cash management to enhance fund efficiency and increase returns for the company and its shareholders [2][3][7]. Summary by Sections Cash Management Overview - The purpose of the investment is to improve fund utilization efficiency without affecting the construction of fundraising projects and normal operations [3]. - The amount of idle raised funds used for cash management is 120 million RMB [2][3]. - The source of funds is temporarily idle raised funds from a previous fundraising effort, which totaled approximately 446.99 million RMB, netting about 444.45 million RMB after expenses [4]. Investment Method - The cash management product purchased is a structured deposit with a principal protection and minimum return feature, ensuring high safety and liquidity [5][6]. - The investment does not alter the intended use of the raised funds and does not harm shareholder interests [5]. Review Procedures - The board of directors and supervisory board approved the cash management proposal on December 18, 2024, with no objections from the independent financial advisor [5][6]. Impact on the Company - The cash management initiative is expected to enhance fund efficiency and profitability, benefiting both the company and its shareholders [7]. - The financial reporting will reflect changes in "trading financial assets," "cash and cash equivalents," "financial expenses," "fair value changes," and "investment income" due to this cash management [7].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●现金管理受托方：华夏银行股份有限公司上海分行 证券代码：600645 证券简称：中源协和 公告编号：2025-039 ●现金管理产品名称：人民币单位结构性存款 DWJCSH25064 中源协和细胞基因工程股份有限公司 关于使用暂时闲置募集资金进行现金管理的进展公 告 ●履行的审议程序：公司于 2024 年 12 月 18 日召开十一届十五次临时董事 会和十一届七次临时监事会，会议审议通过了《关于使用暂时闲置募集资金及自 有资金进行现金管理的议案》。在不影响正常经营、不影响募集资金项目建设和 募集资金使用计划的前提下，同意公司及控股子公司使用不超过人民币 1.2 亿元 的闲置募集资金及不超过人民币 6 亿元的闲置自有资金进行现金管理，自公司董 事会、监事会审议通过之日起 12 个月内有效，在审批期限与授权额度内，资金 可循环滚动使用。 ●特别风险提示：本次投资的结构性存款产品为保本保最低收益型产品，属 于安全性高的投资品种，但产品浮动收益受市场多种因素的影响，收益 ...

Core Viewpoint - Zhongyuan Xiehe announced that its affiliated company, Beijing Sanyouli, in collaboration with Capital Medical University, is progressing with the clinical trials of "human dental pulp mesenchymal stem cell injection" for the treatment of chronic periodontitis, with all participants for Phase II expected to be enrolled by 2024 [1] Group 1 - The company is conducting regular follow-up work for the chronic periodontitis treatment trial [1] - The treatment for idiopathic pulmonary fibrosis has completed all participant dosing in Phase I, and the company is currently organizing clinical safety and efficacy data [1]

证券代码：600645 证券简称：中源协和 公告编号：2025-038 中源协和细胞基因工程股份有限公司 关于用于现金管理的闲置募集资金归还至募集资金 专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2024 年 12 月 18 日召开十一届十五次临时董事会和十一届七次临时 监事会，会议审议通过了《关于使用暂时闲置募集资金及自有资金进行现金管理 的议案》。在不影响正常经营、不影响募集资金项目建设和募集资金使用计划的 前提下，同意公司及控股子公司使用不超过人民币 1.2 亿元的闲置募集资金及不 超过人民币 6 亿元的闲置自有资金进行现金管理，自公司董事会、监事会审议通 过之日起 12 个月内有效。具体详见公司公告：2024-051、052、053。 后公司使用 1.2 亿闲置募集资金购买了华夏银行股份有限公司上海分行人 民币单位结构性存款 DWJGX2510630，产品期限 90 天，成立日 2025 年 6 月 27 日， 到期日 2025 年 9 月 25 日（具体详见公司公告：2025-026）。该产品 ...

Core Viewpoint - Zhongyuan Qihua Cell Gene Engineering Co., Ltd. announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the clinical trial approval notice for VUM02 injection for the treatment of severe/critical pneumonia from the National Medical Products Administration on September 9, 2025 [1]. Drug Information - Drug Name: VUM02 Injection - Dosage Form: Injection - Specification: 5E7 cells (10 mL) per bag - Registration Category: Class 1 therapeutic biological product - Application: Clinical trial registration for domestic drug production - Acceptance Number: CXSL2500507 - Notice Number: 2025LP02332 - Approval Conclusion: The VUM02 injection meets the requirements for drug registration and is approved to conduct clinical trials for severe/critical pneumonia [1]. Clinical Trial Details - The clinical trial plan is a multicenter, randomized, double-blind, placebo-controlled Phase II/III study to evaluate the efficacy and safety of VUM02 injection in treating patients with severe/critical pneumonia [2]. Drug Development Background - VUM02 injection is a cryopreserved cell preparation developed by the company, derived from selected healthy newborn umbilical cord tissue, aimed at treating severe/critical pneumonia [3]. - Severe/critical pneumonia is a common respiratory infectious disease with a high mortality rate of 30%-50%, ranking first in global infectious disease-related deaths [3][4]. - The incidence of community-acquired pneumonia in China is 7.13 per 1,000 person-years, with hospitalization rates increasing annually by 15.5% from 2009 to 2017 [3]. - The global burden of severe/critical pneumonia remains high due to factors such as antibiotic resistance and an aging population, necessitating effective treatment methods [4]. - Mesenchymal stem cells have been applied in various countries for the treatment of severe/critical pneumonia, showing good safety and efficacy [4]. - As of July 2025, the cumulative R&D investment for the related project is approximately RMB 16.56 million [5].

Group 1 - The core point of the article is that Zhongyuan Union has received approval for clinical trials of VUM02 injection for the treatment of severe/critical pneumonia from the National Medical Products Administration [2] Group 2 - The approval was granted to Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhongyuan Union [2] - The approval notification was issued on September 9, 2025 [2]

Group 1 - The core point of the article is that Zhongyuan Qihua has received approval from the National Medical Products Administration for its VUM02 injection to treat severe/critical pneumonia, which could enhance its market position and revenue potential [1] - Zhongyuan Qihua's revenue composition for the first half of 2025 shows that manufacturing accounts for 68.9%, services for 28.3%, and other businesses for 2.79% [1] - As of the report, Zhongyuan Qihua has a market capitalization of 11.6 billion yuan [1]

证券代码：600645 证券简称：中源协和 公告编号：2025-037 中源协和细胞基因工程股份有限公司 关于全资子公司获得药物临床试验批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中源协和细胞基因工程股份有限公司（以下简称"公司"）全资子公司武汉 光谷中源药业有限公司于 2025 年 9 月 9 日收到国家药品监督管理局核准签发的 关于 VUM02 注射液用于治疗重型/危重型肺炎的《药物临床试验批准通知书》。 现对有关信息公告如下： 一、药品基本信息 药品名称：VUM02 注射液 剂型：注射剂 受理号：CXSL2500507 通知书编号：2025LP02332 审批结论： 根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 6 月 23 日受理的 VUM02 注射液符合药品注册的有关要求，同意开展重型/危重型肺炎的 临床试验。 申请人提交的临床试验方案名称：一项以标准疗法为基础治疗评价 VUM02 注射液治疗重型/危重型肺炎患者的有效性和安全性的多中心、随机、双盲、安 慰剂对照的Ⅱ/Ⅲ期临 ...